Will Shrank: The Trillion-Dollar Question Facing CGT Access

Key Takeaways

• Over 4,200 CGT candidates in development, half are gene therapies.
• Global CGT market projected to grow from $9B to $47B by 2035.
• FDA‑approved CGTs cost $0.37‑4.25 million per treatment.
• Payers, providers, manufacturers face unpredictable, high‑cost, one‑time claims.
• Collaborative policy and reimbursement reforms needed within next 3‑5 years.

Pulse Analysis

The cell and gene therapy (CGT) landscape is entering a period of unprecedented expansion. More than 4,200 therapies are in the pipeline, and analysts forecast the market to swell from about $9 billion today to $47 billion by 2035. These products promise curative outcomes, yet their price tags—ranging from $373,000 to $4.25 million per dose—create a financial shockwave that the fragmented U.S. payment system was never designed to absorb. As CGTs move beyond ultra‑rare diseases into common conditions like type 1 diabetes and multiple sclerosis, the volume of high‑cost, one‑time claims will surge, pressuring insurers, employers, and government programs.

Stakeholders across the value chain are feeling the strain. Payers grapple with unpredictable, spike‑laden expenditures that defy traditional actuarial models, while providers must front‑load cash to acquire therapies and wait for reimbursement under single‑case agreements, jeopardizing cash flow and deterring investment in specialized delivery infrastructure. Manufacturers, despite delivering clinically transformative products, encounter lukewarm market launches because the reimbursement architecture cannot keep pace. The result is a misalignment that threatens patient access, slows adoption, and undermines the economic case for continued CGT innovation.

Policy and payment innovation will determine whether the CGT promise translates into real‑world impact. The FDA’s recent flexibilities—such as accelerated approvals and platform‑agnostic pathways—help lower development costs, but sustainable access hinges on new financing mechanisms. Outcomes‑based contracts, risk‑sharing pools, and multi‑payer collaboratives can spread the fiscal burden while tying payment to long‑term value. Aligning incentives among insurers, providers, and manufacturers within the next three to five years will be critical to unlocking the trillion‑dollar potential of curative therapies and ensuring that breakthroughs reach the patients who need them most.